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Abstract
Background: The epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck squamous
cell carcinoma (HNSCC) and several other human cancers. Monoclonal antibodies, such as cetuximab that block
EGFR signaling, have emerged as valuable molecular targeting agents in clinical cancer therapy. Prolonged
exposure to cetuximab can result in cells acquiring resistance by a process that remains incompletely understood.
Methods: In this study, we analyzed the immediate early molecular response of cetuximab on physical interactions
between EGFR and Insulin growth factor 1 like receptor (IGF-1R) in head and neck cancer cells that are resistant to
cetuximab. Co-immunoprecipitation, small molecule inhibitors against phospho-Src and IGF-1R, quantitative western
blot of EGFR and Src phosphorylation, cell proliferation assays were used to suggest the role of IGF-1R mediated
phosphorylation of specific tyrosine Y845 on EGFR via increased heterodimerization of EGFR and IGF-1R in cetuximab
resistant cells.
Results: Heterodimerization of EGFR with IGF-1R was increased in cetuximab resistant HNSCC cell line UMSCC6.
Basal levels of phosphorylated EGFR Y845 showed significant increase in the presence of cetuximab. Surprisingly,
this activated Y845 level was not inhibited in the presence of Src inhibitor PP1. Instead, inhibition of IGF-1R
by picropodophyllin (PPP) reduced the EGFR Y845 levels. Taken together, these results suggest that heterodimerization
of EGFR with IGF-1R can lead to increased activity of EGFR and may be an important platform for cetuximab mediated
signaling in head and neck tumors that have become resistant to anti-EGFR therapy.
Conclusions: EGFR-IGF-1R interaction has a functional consequence of phosphorylation of EGFR Y845 in cetuximab
resistant HNSCC cells and dual targeting of EGFR and IGF-1R is a promising therapeutic strategy.
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Background
Epidermal growth factor receptor (EGFR) is a receptor
kinase that plays essential roles in development. The
EGFR is overexpressed and mutated in several human
cancers including the majority of cases of HNSCC [1].
90 % of HNSCC patients have increased EGFR protein
levels despite the lack of amplification of the EGFR locus
[2]. In addition, the cancer genome atlas (TCGA) has
identified amplification and mutation of EGFR in a pro-
portion of human papillomavirus (HPV) positive and
negative head and neck cancers [3]. This overexpression
of EGFR leads to dysregulated signaling in HNSCC [4].
Inhibition of EGFR using either monoclonal antibodies
(mAbs) against the extracellular domain or small mol-
ecule G-protein coupled receptors (TKI) inhibitors
against the intracellular domain [5], combining mAbs
with radiotherapy [6] and chemotherapy [7], have
resulted in therapeutic benefits [8] including improve-
ment in tumor response and overall survival in can-
cers [9–12]. For instance, the clinical anti-EGFR mAb
cetuximab is capable of interfering with the ligand
binding site of EGFR to downregulate downstream
signaling pathways associated with cell proliferation.
However, there is increasing evidence of acquired
resistance to this antibody [13] necessitating alternate
molecular targets and better strategies for effective
treatment. The onset of EGFR resistance can trigger
alternative signaling pathways through association
with other receptor tyrosine kinases [14, 15] or G-
protein coupled receptors (GPCRs) [16] to maintain
the tumor phenotype but these precise mechanisms
remain only partially understood.
Current technological improvements in genomic and
proteomic platforms [17] have identified many promising
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targets for which inhibitors are being pursued. One such
molecular target is Insulin-like growth factor receptor 1
(IGF-1R). Like EGFR, IGF-1R also plays a role in the
maintenance of the oncogenic phenotype in various can-
cers [18] and is known to mediate anti-apoptotic signals
and cell proliferation [19]. Interaction of insulin like
growth factor I and II (IGF1 and IGF2) with IGF-1R is re-
quired for cell growth, proliferation and apoptosis [20]
while IGF2- IGF1R interaction is not required for adult
growth and development [21]. The recently reported head
and neck cancer TCGA has identified 4 % amplification
and mutation of IGF1R gene in HPV negative HNSCC pa-
tients [3]. Furthermore, activation of IGF-1R has been re-
ported to induce resistance to EGFR TKIs [22].
In this study we investigated the response of HNSCC cell
lines to cetuximab. We found that in cetuximab-resistant
cells there is an increased heterodimerization of EGFR and
IGF1R, in response to cetuximab. Furthermore, the inhib-
ition of EGFR by the IGF-R inhibitor picropodophyllin
(PPP) reduces the EGFR tyrosine 845 phosphorylation
suggesting that the interaction has a consequence on down-
stream signaling pathways. These findings suggest that an
early molecular event following cetuximab binding to EGFR
leads to heterodimerization with IGF-1R to maintain
survival and proliferation of resistant cells and suggests a
potential mechanism for acquisition of resistance.
Methods
All biochemical experiments, cell proliferation and RNA
experiments were performed in triplicates or more.
Cell lines
The human head and neck SCC6 (UM-SCC6) cells were
kindly provided by Dr. Thomas E. Carey (University of
Michigan, Ann Arbor, MI). SCC6 (parental) and cetuxi-
mab resistant clone (resistant) were cultured in Dulbec-
co’s Modified Eagle’s Media supplemented with 10 %
FBS and 1 mg/mL hydrocortisone with 1× penicillin-
streptomycin. Cetuximab resistant clones against EGFR
were developed in SCC6 (parental) background as
described previously [23]. All cell lines were tested for
authenticity in accordance with ATCC guidelines.
Reagents and antibodies
Cetuximab was provided by Imclone systems. Antibodies
against total EGFR, IGF1R, Src, phospho-EGFR tyrosine
845, phospho-Src tyrosine 416, GAPDH and mouse im-
munoprecipitation (IP) specific antibody were obtained
from Cell Signaling Technology (Beverly, MA). Anti-
IGF1R for IP experiments was obtained from Life Tech-
nologies, (Carlsbad, CA). All other secondary antibodies
were obtained from Cell Signaling Technology (Beverly,
MA). 1-(1,1-dimethylethyl)-3-(4-methylphenyl)-1H-pyra-
zolo[3,4-d]pyrimidin-4-amine (PP1) Src inhibitor was
obtained from Biomol GmbH. Picropodophyllin (PPP)
and AG1024 was obtained from Santa Cruz Biotechnol-
ogy Inc (Santa Cruz, CA). Dasatinib was obtained from
Cayman chemicals (Ann Arbor, MI). Cell culture media
and supplements were obtained from Life Technologies,
Inc. (Carlsbad, CA).
Protein extraction
SCC-6 sensitive and cetuximab resistant cells were ex-
tracted in a protein extraction buffer which consisted of
25 mM HEPES buffer, pH 7.9, 1 U/μLof Benzonase
1 mM MgCl, 5 mM EDTA and 1 tablet of EDTA free
protease inhibitor and PhosSTOP (Roche) per 10 ml of
buffer. To this, an optimized mixture of detergents was
added comprised of 0.5 % TrX100, 0.5 % NP-40S, 0.5 %
cholic acid sodium salt (Cholate), 0.25 % n-dodecyl-β-D-
maltoside and 0.25 % 3-[(3 cholamidopropyl) dimethy-
lammonio]-1-propanesulfonate (CHAPS). Cells were
treated with 10 μg/ml cetuximab and harvested at 80 %
confluence, washed two times with ice-cold PBS, scraped
with cell scraper and pelleted at 20,000 g for 10 min and
homogenized with motorized homogenizer for 1 min.
The mixture was centrifuged at 20,000 g for 10 min at
4 °C. The resultant pellet was resuspended, rehomo-
genized and then recentrifuged at 20 000 g for
10 min at 4 °C. The supernatant was transferred into
fresh tube and concentration was determined with the
bicinchoninic acid (BCA) Protein Assay Reagent
(Thermo Scientific).
SDS-PAGE and western immunoblot analysis
Protein extracts was mixed with 4× Laemmli buffer
Laemmli buffer (Bio-rad, Hercules, CA) boiled in a heat-
ing block at 95 °C for 5 min,loaded and electrophoretic-
ally separated onto a 4–20 % gradient tris-glycine
polyacrylamide gel (Bio-rad) Subsequently, the gels were
transferred to low fluorescent nitrocellulose membrane
using the turbo-blot system (Bio-rad) following the man-
ufacturer’s instructions. The membranes were stained
with 0.1 % Ponceaus S in 1 % acetic acid for monitoring
transfer and equal loading and blocked with 5 % nonfat
dry milk. Following blocking, the membranes wereincu-
bated with primary antibodies at 1:1000 dilution in 5 %
BSA in Tris buffered saline with 0.1 % Tween-20 (TBST)
at 4 °C overnight. Incubation with peroxidase-labeled
secondary mouse or rabbit antibodies was carried out at
was conducted at room tem-perature for 1 h, followed
by 3 washes times 5 min with TBST. Bands were ex-
posed after addition of the GE ECL Prime kit (GE
healthcare, USA) and digitally recorded using a LI-COR
Fc imaging system. All western blots were repeated in
triplicate. For Figs. 1c, d and 4b, d, Immunoblots were
imaged using an Odyssey infrared imaging system Fc
(LI-COR Biosciences). Scan resolution of the instrument
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was fixed at 125 μm and images were acquired at inte-
gration times of 30 s. Quantification was performed with
Image studio lite software. The median pixel intensity
quantified for each band was normalized to GAPDH
which served as the loading control. The experimental
intensity values of experimental was divided with
GAPDH and graphed with Originlab software. All exper-
iments were performed in triplicates.
Co-immunoprecipitation
UMSCC6 cetuximab sensitive and resistant cells were
plated (on day 1) at a density of 4 million cells per
15 cm dish and treated with 10 μg/ml on the 3rd day
and harvested at 5, 60 and 120 min with 0 min serving
as control untreated sample. Treated cells were har-
vested on day 3 by scraping cells with a cell scraper
(Corning Inc., Corning, NY), and cells transferred to a
1.5 mL conical tube (Wilmad Glass, NJ) for centrifuga-
tion and lysis as described for immunoblot procedure
above. 1 mg/ml of total protein was precleared with 30
ul of Protein G Dynabeads and incubated with pre-
formed complexes of protein G Dynabeads (Invitrogen,
Carlsbad, CA) and mouse anti- EGFR and rabbit IGF-1R
antibodies (CST, Beverly, MA and Life Technologies,
Carlsbad, CA) at room temperature was end to end
mixed on a rocker for 30 min and further at 4 °C for
3 h. The antigen-antibody complexes were collected
using a magnet and washed with 1× PBS containing
0.1 M NaCl, 0.5 M NaCl and 0 M salt progressively.
Complexes were dissociated by incubating in reducing
buffer (4× Laemmli buffer for 5 min at 95 °C. The boiled
samples was cooled on ice and removed from beads
using a magnet and loaded onto a 4–20 % gradient SDS-
PAGE gel for western analyses.
Quantification of mRNA expression
Relative mRNA levels of EGFR and IGF-1R were quanti-
fied via real-time PCR (RT-qPCR) using a Bio-Rad
C1000 qPCR Detection System and Power SYBR Green
PCR Master Mix as recommended by the manufacturer
(Life Technologies). All reactions were performed in
triplicate from RNA isolated from three independent
biological experiments. The geometric mean of four
housekeeping genes (β-Actin, β-Microglobulin, GAPDH,
HPRT1) was calculated and used for normalization
(Additional file 1: Table S1). Fold increases or decreases
in gene expression after treatments were normalized to
an untreated control sample at time zero.
Cell viability assay
For Fig. 1a, cetuximab resistant and sensitive cells previ-
ously described in (23) were continuously exposed to
increasing concentrations of cetuximab for over a period
of 3 weeks to evaluate its sensitivity to cetuximab.
Commencing with the IC50 of cetuximab, the exposure
dose was progressively doubled every 10–14 days until 7
~ 8 dose doublings had been successfully achieved. In
parallel, controlled parental cells were exposed to corre-
sponding vehicle, PBS. Exponentially growing cells were
seeded in 6 well plates. Following the treatment, cells
were then washed with PBS and fixed/stained with 0.5 %
crystal violet. Plates were air dried overnight and dye
was eluted with 0.1 M sodium citrate (pH 4.2) in ethanol
(1:1). Elution was transferred to 96 well plates, and the
absorbance was read at 540 nm to determine cell viabil-
ity and untreated cells were normalized to 1.
Cell proliferation assay
The CCK-8 assay was used to measure cytotoxicity, based
on the conversion of a water-soluble tetrazolium salt, 2-
(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disul-
fophenyl)-2H-tetrazolium, monosodium salt (WST-8), to
a water-soluble formazan dye upon reduction by dehydro-
genases in the presence of an electron carrier. HCECs
(2.5 × 104 cells/ml) were grown in 96-well plates for 48 h
and treated with inhibitors PP1, Dasatinib, PPP with or
without cetuximab antibody, wherever applicable. After
36 h, cells were washed, and the extent of cell growth was
assessed using a CCK-8 assay (Dojindo, Kumamoto,
Japan). CCK-8 solution (10 μl) was added to each well,
followed by incubation for 2 h at 37 °C. The absorbance at
450 nm was determined by a multiplate reader (Lambda
Bio-20; Beckman). Cell viability was expressed as a per-
centage of that of the control (untreated) cells. The mean
values of the mean absorbance rates from eight wells and
percentage coefficient of variation were calculated and
graphed using Originlab software.
Results
We sought to examine signaling activation in the con-
text of acquired resistance to the anti-EGFR antibody,
cetuximab, in the previously described squamous head
and neck carcinoma line UMSCC6 (University of
Michigan squamous cell carcinoma) [23]. We first
confirmed the stability of the UMSCC6 cetuximab
resistant cell lines to challenge with varying concen-
trations of cetuximab. For this purpose, resistant cells
were maintained in media in the presence or absence
of cetuximab for 17 passages and compared to paren-
tal cetuximab sensitive cells. Using a crystal violet
assay, we established that the proliferative capacity of
resistant cells remained unchanged irrespective of
cetuximab in the media while the sensitive cells had
50 % proliferation at similar concentrations of cetuximab
(Fig. 1a). Having established the resistance phenotype and
observed 50 % reduction in proliferation in the sensitive
cells, we performed all experiments at 10 μg/ml cetuximab
concentration.
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To determine the immediate early effects of perturb-
ation on EGFR with cetuximab, we compared the levels
of EGFR protein in both sensitive and resistant cell lines.
Total EGFR levels increased modestly in both resistant
and sensitive with increasing time of exposure to cetuxi-
mab (Fig. 1b and c). We next asked if cetuximab had
any local effect on IGF-1R. IGF-1R, a RTK known to be
involved in malignant transformation and expressed in
tumors was upregulated in resistant cells when com-
pared to sensitive cells (Fig. 1b and c). Furthermore,
quantification of the immunoblots revealed that IGF-1R
protein level was induced by two- fold within 2 h of
exposure to cetuximab in resistant cells (Fig. 1c). In the
same time period, EGFR levels are induced 1.4 and 1.2
fold respectively in resistant and sensitive cells (Fig. 1c).
Taken together, the quantitative analyses suggested that
cetuximab increased the levels of IGF-1R in resistant
cells when compared to sensitive cells.
We next investigated whether this increased IGF1R
level had a functional consequence in the SCC cells.
Mechanistically, blocking the ligand binding site of EGF
with cetuximab could result in signaling or activation of
IGF-1R or sustained engagement of adaptor proteins via
receptor heterodimerization, thus enabling an alternative
pathway for survival and proliferation. Therefore we
assessed the levels of heterodimerization of IGF-1R and
EGFR in resistant and sensitive cells. In resistant cells
treated with cetuximab, increasing amounts of IGF-1R
protein were observed in the EGFR immunoprecipitate
with time of exposure (Fig. 2a). The interaction of EGFR
Fig. 1 IGF-1R increase in resistant cells upon exposure to anti-EGFR antibody cetuximab. a UMSCC6 cetuximab resistant and sensitive cell lines at
passage 17 were exposed to increasing concentration of cetuximab to measure cell viability by absorbance in a crystal violet assay (■) Resistant
cells in the absence of cetuximab, (●) sensitive cells in the presence of cetuximab (▲) resistant cells in the presence of cetuximab. b Representative
blot of total EGFR and IGF-1R show increased levels in cetuximab resistant cells relative to parental cells. c, d Quantitation of total EGFR and IGF-1R
levels normalized to GAPDH from four independent experiments
Iyer et al. BMC Cancer  (2016) 16:773 Page 4 of 11
and IGF-1R was detected as early as 5 min and remained
sustained to 120 min (Fig. 2a) mirroring the increasing
levels of IGF1R total protein (Fig. 1c). By comparison, in
sensitive cells, the relative amount of IGF1R co-
immunoprecipitated with EGFR remained constant with
time (Fig. 2b). In both cell lines, the reciprocal IGF-1R
co-immunoprecipitation did not reveal increasing amounts
of EGFR (Fig. 2a and b).
The lack of increased EGFR in the immunoprecipi-
tate of IGF-1R in the resistant line could be due to
the technical reasons such as the better precipitation
capability of the EGFR antibody. Analysis of the
supernatant after the immunoprecipitation by anti-
EGFR revealed that almost 100 % of the protein had
been removed from the lysate (Fig. 2c); by contrast
about 33 % of the IGFR protein was left behind in
the supernatant after immunoprecipitation (Fig. 2d).
In addition, in the IGF1R immunoprecipitate, if
there is a 1:1 stoichiometry, only 1/4th of the EGFR
molecules would be precipitated which could be
undetectable. Taken together, these results suggest
that cetuximab may activate EGFR to heterodimerize
with IGF-1R and this interaction increases over time
in resistant cells.
We next determined if there was a functional conse-
quence of increased IGF1R in the UMSCC-1 cetuximab
resistant line. We performed siRNA-mediated knock-
down of EGFR and IGF1R in both resistant and cell lines
with 3 independent siRNAs and normalized the knock-
down levels with four housekeeping genes (Additional
file 1: Table S1). Efficient knockdown of up to 90 % was
observed at the transcript level in both lines (Fig. 3a).
Multiple siRNAs were tested to minimize off-target
effects (Fig. 3a). Both EGFR and IGF1R levels were
also reduced at the protein level (Fig. 3c and d) at
72 h post transfection of siRNA. Utilizing a cell via-
bility assay we assessed the effect of the knockdown
on cell proliferation after 72 h of depletion of the
EGFR and IGF1R protein. Compared to the untreated
and non-targeting control, under reduced levels of
EGFR and IGF1R, there were reduced cell numbers in
the resistant cell line of up to 67.98 and 57.8 % re-
spectively (Fig. 3e). In contrast, at this time point the
cell numbers in the sensitive were not significantly chan-
ged (Fig. 3e). These observations suggest that reducing
levels of IGF1R can retard the growth rate of resistant
cells suggesting a functional role.
We next examined if heterodimerization of EGFR and
IGF-1R caused any change in EGFR tyrosine phosphor-
ylation states. Autophosphorylation sites Y992, Y1045
and Y1148 on EGFR revealed constitutive basal level of
phosphorylation compared to untreated cells in the
presence of cetuximab. However, Y1068 showed higher
levels of phosphorylation in both resistant and sensitive
cells compared to untreated cells suggesting an engagement
of RAS signaling pathway (Additional file 1: Figure S3).
While these autophosphorylation signals in the pres-
ence of cetuximab was intriguing in the presence of
cetuximab, we focused on Tyrosine 845 in EGFR,
which is present in the activation segment of the
kinase domain of EGFR as it has been implicated in
cell proliferation and migration in several cancers
Fig. 2 IGF-1R interaction with EGFR increases with cetuximab treatment in resistant cells. a Co-immunoprecipitation (IP) of EGFR and IGF-1Rβ in
resistant cell lysates with increasing time of exposure to cetuximab. Reciprocal immunopreciptations with either EGFR or IGF1R are presented
in right and left panels respectively. b As in A, but for sensitive cell lysates. c EGFR western blot in input and supernatant (sup) after IP with
anti-EGFR in resistant cell lysate. 5 % of each sample is loaded. d as in C but for anti-IGF1R in resistant cell lysate
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[24]. To address this, we probed for EGFR Y845 as a
function of time and cetuximab treatment up to 2 h.
There was an increase in Y845 phosphorylation in re-
sistant cells relative to the untreated condition while
levels remained relatively constant in sensitive cells
(Fig. 4a). Y845 phosphorylation increased by 3-fold in
2 h (Fig. 4b).
The tyrosine kinase Src can phosphorylate EGFR at
Y845 [25, 26]. Prior to Src activity on targets, auto-
phosphorylation of its own catalytic site at position
Y416 is required. Therefore we monitored whether
Src-Y416 was also altered in its phosphorylation sta-
tus in a similar manner to EGFR. We found the level
of pSrc-Y416 was 1.60 fold higher in the resistant
compared to sensitive cells (Fig. 4c and d). Further-
more, addition of cetuximab increased the levels of
pSrc-Y416 about 2-fold in both resistant and sensitive
cells at 120 min.
We next explored whether there was a relationship
between the increase in p-SrcY416 and p-EGFR-Y845
without altering endogenous levels and hence used Src
inhibitors in the presence of cetuximab. PP1with an
IC50 of 170 nM is a potent selective dual site inhibitor
of Src non-receptor tyrosine kinase family members
which acts as a competitive inhibitor of ATP [27]. An
inhibitor concentration of 10 μM previously reported to
reduce the Src activity and level of EGFR Y845 [28] was
used up to 120 min in both resistant and sensitive cells.
Analyses of immunoblots from sensitive and resistant
cells treated with PP1 inhibitor probed with Src family
kinase-specific pY416 antibody revealed clearly that Src
activity was diminished in both sensitive and resistant
cells compared to untreated cells (Fig. 4f ). Surprisingly,
the levels of EGFR-Y845 did not reduce greatly in the
presence of PP1and cetuximab, especially in the resistant
cells (Fig. 4e). However, resistant and sensitive cells
exposed to PP1 inhibitor showed reduced proliferation
of approximately 60 and 76 % respectively (Fig. 4i)
compared to untreated cells. To confirm this reduced
effect of Src inhibition, we used Dasatinib, an alternative
Src inhibitor with an IC50 of 0.8 nM. Similar to the PP1
results, in the presence of Dasatinib, pSrc-Y416 levels
were reduced in both resistant and sensitive cells
(Fig. 4h) while Y845 levels remained unchanged (Fig. 4g)
compared to untreated cells. Quantification of Y845



















































































Fig. 3 Knockdown of IGF-1R reduces the proliferation of resistant cells. a Relative expression of EGFR and IGF1R in resistant cells subjected to
knockdown with three independent siRNAs targeting EGFR or IGF1R respectively after 60 h. Scrambled control was set to 1. b as in A but for the
sensitive cell line. c Representative western blot indicating reduced levels of EGFR (left panel) or IGF1R (right panel) after knockdown with siRNA
#1 and #8 respectively in resistant cells. GAPDH was used as a loading control protein was quantified at 60 h. d As in C but for the sensitive cell
line. e Proliferation of resistant and sensitive cell lines in untreated, scrambled and specific knockdown conditions, measured using the CCK-8
assay, measured at 72 h. IGF1R has a greater effect on proliferation in resistant as compared to sensitive cells
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Fig. 4 (See legend on next page.)
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further indicated that combined effect of PP1, dasati-
nib and cetuximab did not significantly diminish the
phosphorylation state of EGFR Y845 (Additional file
1: Figure S2A, B). Taken together, the immediate
early effects of cetuximab treatment suggested that
EGFR Y845 levels increased despite the reduced
activity at p-SrcY416. Furthermore, we tested if
transactivation of EGFR Y845 could be mediated by
IGF-1R as there was increased hetero-dimerization
between EGFR and IGF-1R as observed in Fig. 2b.
Indeed, siRNA mediated knock down of IGF-1R
reduced Y845 phosphorylation state to almost un-
detectable levels (Additional file 1: Figure S1). This
result further validated the co-immunoprecipitation
of IGF-1R and EGFR (Fig. 2a, b) and IGF-1R’s
plausible role in phosphorylating EGFR Y845 phos-
phorylation in the presence of cetuximab.
Like EGFR, IGF-1R is involved in normal cellular
growth as well as transformation and progression of
malignancy in various cancers [29]. PPP with an IC50 of
1 nM is a specific inhibitor of IGF-1R. To determine if
inhibition of kinase activity of IGF-1R had an influence
on EGFR Y845 due to their hetero-dimerization, resist-
ant and sensitive cells were exposed to picropodophyllin
(PPP) at 0.5 μM for 120 min. Interestingly, PPP com-
pletely reduced Y845 phosphorylation at 120 min in
both resistant and sensitive cells compared to untreated
cells, (Fig. 5a). To confirm these results, we tested
another inhibitor of IGF-1R, AG1024 which has an IC50
of 0.4 μM. AG1024 effects were more gradual than that
of PPP showing reduced levels of Y845 only at later time
points in the resistant line, (Fig. 5b). This data suggests
that in the resistant line, where there is more hetero-
dimerization of EGFR-IGF1R leading to greater Y845
levels, the less potent inhibitor AG1024 can act rapidly.
In the sensitive cell line these heterodimers are less
frequent; hence the potent PPP inhibitor can act to
remove the phosphorylation at Y845 rapidly. A com-
bined treatment of resistant and sensitive cells with PPP
and cetuximab showed 39 and 54 % reduced prolifera-
tion while PPP showed a reduction of 51 and 41 %
(Additional file 1: Figure S4A) while a similar trend of
reduced proliferation was also observed with another
IGF-1R inhibitor,AG1024 (Additional file 1: Figure S4B).
This result suggested that PPP and AG1024 can act
together with cetuximab to impede the cell growth of
these cell lines.
Discussion
Systematic preclinical investigation of anti-EGFR signal-
ing agents in human tumor cells and animal model sys-
tems has proven valuable in the logical design of clinical
trials testing EGFR inhibitors [9]. As with virtually all
anti-cancer drugs, chronic exposure to EGFR inhibitors
eventually induces molecular changes that confer vary-
ing degrees of drug resistance. For the EGFR system,
one mechanism of acquired resistance involves upregula-
tion of collateral receptor tyrosine kinases (RTKs) that
provide escape from the selection pressure of EGFR
blockade [30–32]. For example, interactions between the
EGFR, IGF-1R and VEGFR signaling pathways are well
(See figure on previous page.)
Fig. 4 Phosphorylation of EGFR Y845 is not inhibited with Src inhibitors PP1 and Dasatinib. a EGFR Y845 levels show increased levels in response
to cetuximab with time in resistant cells (left panel) and constant levels in sensitive cells (right panel). b Quantitation of EGFR Y845 normalized to
GAPDH from four independent experiments after increasing times of exposure to10 μM of PP1. c phospho-Src Y416 show increased levels
in response to cetuximab with time in resistant cells (left panel) and constant levels in sensitive cells (right panel). d Quantitation of p-Src
Y416 normalized to GAPDH from four independent experiments after increasing times of exposure to cetuximab. e Representative western
blot of EGFR Y845 show constant levels in response to PP1 in both resistant cells (left panel) and sensitive cells (right panel) in presence
of cetuximab. f Representative western blot of p-Src 416 show reducing levels in response to PP1 in both resistant cells (left panel) and
sensitive cells (right panel) with increasing time. g As in E above but after exposure to Dasatinib. h As in E above but after exposure to
Dasatinib. i Proliferation of resistant and sensitive cell lines after exposure to PP1 for 72 h, measured using the CCK-8 assay
Fig. 5 Phosphorylation of EGFR Y845 is reduced with IGF-1R specific
inhibitor picropodophyllin (PPP). a Representative western blot of
EGFR Y845 show decreased levels in response to 0.5 μM concentra-
tion PPP with time in both resistant cells (left panel) and in sensitive
cells (right panel) The inhibitory effect of PPP is more rapid in resist-
ant as compared to sensitive cells. b similar treatment times as in
(a), but monitored effect using 10 μM AG1024, another inhibitor of
IGF-1R. Note that AG1024 is less inhibitory to IGF1R than PPP
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established and target inhibition within one system
commonly impacts molecular signaling (and ultimately
tumor response) via compensatory response from com-
panion RTK pathways [10–12]. In the current study, we
identify a specific molecular interaction between EGFR
and IGF-1R that may play a role in resistance to cetuxi-
mab, the leading anti-EGFR inhibitory agent in current
clinical use for cancer therapy. This may stimulate op-
portunities to further refine the response and resistance
profile for cetuximab therapy in the future.
Signaling from the EGFR is affected by several param-
eters. For example the number of EGFR on the cell
surface can affect the extent of signaling [33]. The ligand
binding site of EGFR can have high or low affinity for
EGF giving rise to two distinct population of receptors
[34]. The outcome of EGFR signaling can vary with
whether low or high affinity receptors are activated [35,
36]. EGFR can exist as monomers or preformed dimers
on the cell surface [37]. Binding of EGF ligand promotes
dimerization of the EGFR [38]. Since HNSCC cells
overexpress EGFR, the number of dimers is likely to be
increased. Binding of cetuximab leads to disruption of
EGFR dimers in both resistant and sensitive HNSCC.
The resultant effect is increased monomers of EGFR on
the cell surface. Since IGF-1R levels are increased in
resistant cells (Fig. 1b and c), this increases the probabil-
ity of engagement of EGFR with IGF-1R causing hetero-
dimerization (Fig. 2b). Preliminary observations using
high resolution imaging suggests that there is increased
clustering of EGFR and IGF-1R in the presence of
cetuximab (unpublished results). This EGFR-IGF-1R
interaction could provide an alternative signaling plat-
form for maintenance of the resistant phenotype.
EGFR-IGF-1R heterodimerization has been reported in
drug resistant cancers, for example in non-small cell
lung cancer (NSCLC), heterodimerization of EGFR and
IGF-1R was increased upon exposure to the EGFR tyro-
sine kinase inhibitor, erlotinib [39], but the consequence
of dimerization has remained poorly understood. In our
study, we found that EGFR-IGF-1R interaction has a
functional consequence of phosphorylation of EGFR
Y845. The analysis of EGFR Y845 phosphorylation
revealed it to be constitutively phosphorylated in both
sensitive and resistant cells, albeit, the levels of
EGFRY845 phosphorylation increased with time in the
resistant cells (Fig. 4a). This site is a read out for EGFR
activation and downstream signaling output [40]. The
non-receptor tyrosine kinase Src is thought to be in-
volved in EGFR Y845 phosphorylation [25, 26]. Further-
more, Src family kinases has been suggested to increase
the EGFR Y845 levels in cetuximab resistant clones
derived from lung NCI-H226 cells [41] and also impli-
cated in erlotinib resistance in head and neck cancer
[42]. However, abrogation of pSrc-Y416 phosphorylation
by Src specific inhibitors PP1 and dasatinib did not
decrease EGFR Y845 levels (Fig. 4e, g). In addition,
siRNA knockdown also suggested reduced EGFR Y845
levels (Additional file 1: Figure S1). This result would
suggest that heterocomplex of EGFR-IGF-1R in the
presence of cetuximab may have adopted a conform-
ation which prevents Src to access this Y845 located in
the activation loop of EGFR (Fig. 6). Intriguingly, we
observed the loss of EGFR Y845 phosphorylation upon
treatment with IGF-1R inhibitor, PPP which suggested
that heterodimerization is important for conferring
this phosphorylation. Recent reports indicate that PPP
has the ability to inhibit the phosphorylation status of
EGFR in combination with erlotinib or alone in head
and neck cancer [43].
Sharpening our understanding of resistance mecha-
nisms to molecular targeting agents like cetuximab may
illuminate opportunities to refine treatment strategies
that increase tumor response and control rates. Our
results suggest that a combinatorial approach that in-
hibits both EGFR and IGF1R signaling may offer a
worthy strategy to enhance therapeutic outcome and
combat acquired resistance to cetuximab in head and
neck cancer. We are pursuing preclinical studies in tis-
sue culture and animal model systems to further explore
the potential value of this approach.
Fig. 6 Model of cetuximab induced EGFR and IGF-1R interaction.
Binding of anti-EGFR antibody cetuximab displaces the EGF ligand
which results in disruption of EGFR homodimers. Cetuximab bound
monomer of EGFR engages IGF-1R to form a heterodimer. The
ligand independent activation of EGFR Y845 is not reduced in
the presence of Src inhibitor PP1 (dotted line) but is reduced by
IGF-1R inhibitor PPP. The model suggests that intrinsic kinase
activity of IGF-1R has the potential to phosphorylate EGFR Y845
due to the heterodimerization of these receptors. This heterodimerization
and hence sensitivity to IGF1R mediated phosphorylation is more
pronounced in resistant than sensitive cells
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Conclusions
Based on our observations, EGFR-IGF-1R interaction
has a functional consequence of phosphorylation of
EGFR Y845 in cetuximab resistant HNSCC cells. Target-
ing of EGFR and IGF-1R in a spatio-temporal manner
could be a promising therapeutic strategy in head and
neck cancer.
Additional file
Additional file 1: Table S1. List of sequences for siRNA and
housekeeping genes used in this study. Figure S1. Knockdown
of IGF-1R diminishes the phosphorylation state of EGFR Y845.
Representative western blot indicating reduced levels of EGFR Y845
in both cetuximab resistant and sensitive cells. GAPDH was used
as a loading control protein was quantified at 60 h. Figure S2.
Quantitation of phosphor-EGFR Y845 normalized to GAPDH from
four independent experiments after increasing times of exposure
to combined inhibition with PP1 and cetuximab. A) Addition of
PP1 or B) dasatinib with cetuximab shows increased Y845 levels
relatively in resistant cells treated while in sensitive cells, there is
marginal increase suggesting lack of inhibition when Src inhibitors
are combined with cetuximab. Figure S3. Effect of cetuximab on
auto-phosphorylation sites of EGFR. Constitutive basal levels of
autophosphorylation was detected for Y992, Y1045 and Y1148 in
the presence of cetuximab in both resistant and sensitive cells
while for Y1068 there was higher signal intensity compared to
untreated cells suggesting immediate activation of the RAS signaling
cascade in the presence of cetuximab. Figure S4. Combined inhibition of
EGFR and IGF-1R leads to reduced proliferation compared to IGF-1R alone.
A) Combination of 0.5 μM PPP, an IGF-1R inhibitor with 66.6 nM cetuximab
leads to reduced cell proliferation when compared to single inhibitor
treatment of PPP alone. B) A similar trend was also observed with
another IGF-1R inhibitor, AG1024. All experiments were performed in
quadruplicates thrice independently. (DOCX 441 kb)
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